KYMR vs. ADMA, APGE, BEAM, RXRX, VCEL, SANA, NVAX, DNA, FUSN, and CGON
Should you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include ADMA Biologics (ADMA), Apogee Therapeutics (APGE), Beam Therapeutics (BEAM), Recursion Pharmaceuticals (RXRX), Vericel (VCEL), Sana Biotechnology (SANA), Novavax (NVAX), Ginkgo Bioworks (DNA), Fusion Pharmaceuticals (FUSN), and CG Oncology (CGON). These companies are all part of the "biological products, except diagnostic" industry.
Kymera Therapeutics (NASDAQ:KYMR) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership.
In the previous week, Kymera Therapeutics had 3 more articles in the media than ADMA Biologics. MarketBeat recorded 5 mentions for Kymera Therapeutics and 2 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.59 beat Kymera Therapeutics' score of 0.18 indicating that ADMA Biologics is being referred to more favorably in the news media.
ADMA Biologics has a net margin of -1.29% compared to Kymera Therapeutics' net margin of -194.67%. ADMA Biologics' return on equity of 17.24% beat Kymera Therapeutics' return on equity.
ADMA Biologics received 366 more outperform votes than Kymera Therapeutics when rated by MarketBeat users. Likewise, 71.68% of users gave ADMA Biologics an outperform vote while only 47.56% of users gave Kymera Therapeutics an outperform vote.
Kymera Therapeutics has a beta of 2.31, meaning that its share price is 131% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.
Kymera Therapeutics presently has a consensus target price of $41.10, suggesting a potential upside of 17.66%. ADMA Biologics has a consensus target price of $10.50, suggesting a potential upside of 8.58%. Given Kymera Therapeutics' higher possible upside, equities research analysts plainly believe Kymera Therapeutics is more favorable than ADMA Biologics.
75.7% of ADMA Biologics shares are owned by institutional investors. 15.8% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
ADMA Biologics has higher revenue and earnings than Kymera Therapeutics. ADMA Biologics is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
ADMA Biologics beats Kymera Therapeutics on 12 of the 19 factors compared between the two stocks.
Get Kymera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kymera Therapeutics Competitors List
Related Companies and Tools
